Liver Cirrhosis - Pipeline Review, H2 2019

Published by Global Markets Direct on 11th November 2019 | Ref: 1463986 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Liver Cirrhosis - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H2 2019, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape.

Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cirrhosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Liver Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 3, 12 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Liver Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cirrhosis (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Liver Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Liver Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Liver Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cirrhosis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Liver Cirrhosis (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Liver Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Liver Cirrhosis - Overview

Liver Cirrhosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Liver Cirrhosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Liver Cirrhosis - Companies Involved in Therapeutics Development

Advantagene Inc

AlfaSigma SpA

Bristol-Myers Squibb Co

Galectin Therapeutics Inc

Gilead Sciences Inc

Grifols SA

International Stem Cell Corp

Mina Therapeutics Ltd

Novo Nordisk AS

Pharmicell Co Ltd

Promethera Biosciences SA

Rohto Pharmaceutical Co Ltd

Versantis AG

VESSL Therapeutics Ltd

Liver Cirrhosis - Drug Profiles

7-E - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADR-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

albumin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCD-800 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

belapectin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986263 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellgram-LC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate MMP8 for Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate ZSCAN4 for Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GXHPC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HepaStem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAE-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAE-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAE-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAE-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTL-CEBPA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-654 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NN-9931 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OC-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegbelfermin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit C/EBP-Beta for Gastrointestinal and Respiratory Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRI-724 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rifaximin SSD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TLY-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Liver Cirrhosis - Dormant Projects

Liver Cirrhosis - Discontinued Products

Liver Cirrhosis - Product Development Milestones

Featured News & Press Releases

Sep 17, 2019: Galectin Therapeutics and Providence Cancer Institute receive patent on the use of Belapectin (GR-MD-02) in Cancer Immunotherapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1463986 | GMDHC11434IDB

Number of Pages

106

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
11-04-2017

$2,000 USD

Published by Global Markets Direct
22-03-2017

$2,000 USD

Published by Global Markets Direct
28-02-2017

$2,000 USD

Published by Global Markets Direct
30-12-2016

$2,500 USD

Published by Global Markets Direct
21-12-2016

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Liver Cirrhosis - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.